Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 12/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1497783 | 0.89 | ADORA1 (0.88) | ADORA1 | |
| SCHEMBL1497837 | 0.87 | ADORA1 (1.00) | ADORA1MEN1KMT2ARAB9A | |
| SCHEMBL1497855 | 0.86 | ADORA1 (0.77) | ADORA1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL12758721 | 0.86 | ADORA1 (1.00) | ADORA1ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL1497952 | 0.86 | ADORA1 (1.00) | ADORA1KDM4ELMNA | |
| SCHEMBL1497774 | 0.84 | ADORA1 (0.82) | ADORA1MAPT | |
| SCHEMBL1497621 | 0.84 | ADORA1 (0.77) | ADORA1 | |
| SCHEMBL1497826 | 0.84 | ADORA1 (0.87) | ADORA1ALDH1A1MAPTMAPK1KDM4E | |
| SCHEMBL1497891 | 0.84 | ADORA1 (0.77) | ADORA1HRH3 | |
| SCHEMBL1497817 | 0.83 | ADORA1 (1.00) | ADORA1ALDH1A1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053917-A1 | Allosteric Modulators of the A1 Adenosine Receptor | BARALDI PIER GIOVANNI | 2011-03-03 | — | — | US | claimed |
| US-7855209-B2 | Allosteric modulators of the A1 adenosine receptor | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-12-21 | — | — | US | claimed |
| EP-2081575-A2 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | King Pharmaceuticals Research and Development Inc. (US) | 2009-07-29 | — | — | EP | claimed |
| US-20080125438-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-29 | — | — | US | claimed |
| WO-2008063984-A2 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| US-20110053917-A1 | Allosteric Modulators of the A1 Adenosine Receptor | BARALDI PIER GIOVANNI | 2011-03-03 | — | — | US | disclosed |
| US-20110053917-A1 | Allosteric Modulators of the A1 Adenosine Receptor | BARALDI PIER GIOVANNI | 2011-03-03 | — | — | US | disclosed |
| US-20110053917-A1 | Allosteric Modulators of the A1 Adenosine Receptor | BARALDI PIER GIOVANNI | 2011-03-03 | — | — | US | disclosed |
| US-7897596-B2 | {2-Amino-4-[(4-(4-chlorophenyl)piperidin-1-yl)methyl]thiophen-3-yl}(4-chlorophenyl)methanone; analgesic, antidepressant; cardiac disease or disorder, neurological disease or injury, sleep disorder, epilepsy, neuropathic pain, angina | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897596-B2 | {2-Amino-4-[(4-(4-chlorophenyl)piperidin-1-yl)methyl]thiophen-3-yl}(4-chlorophenyl)methanone; analgesic, antidepressant; cardiac disease or disorder, neurological disease or injury, sleep disorder, epilepsy, neuropathic pain, angina | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897596-B2 | {2-Amino-4-[(4-(4-chlorophenyl)piperidin-1-yl)methyl]thiophen-3-yl}(4-chlorophenyl)methanone; analgesic, antidepressant; cardiac disease or disorder, neurological disease or injury, sleep disorder, epilepsy, neuropathic pain, angina | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7855209-B2 | Allosteric modulators of the A1 adenosine receptor | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| WO-2008147939-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080125438-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125438-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125438-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008063984-A2 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080119460-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119460-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119460-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119460-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885ALDH1A1 246/4885MEN1 4219/4885 |
| US-20080125438-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885ALDH1A1 246/4885MEN1 4219/4885 |
| US-20110053917-A1 | Allosteric Modulators of the A1 Adenosine Receptor | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885ALDH1A1 209/4885MEN1 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.